Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises the sellers in connection with the divestment of Johan i Hallen & Bergfalk
Mandate

Vinge advises the sellers in connection with the divestment of Johan i Hallen & Bergfalk

May 04, 2023 Banking and Finance M&A

Vinge advises the sellers, represented by Litorina V Fund, in connection with the divestment of JOHBECO AB (including its Swedish and Finnish subsidiaries Johan i Hallen & Bergfalk) to METRO FSD Holding GmbH, an indirect subsidiary of international wholesaler METRO AG.

Johan i Hallen & Bergfalk operates on the Swedish and Finnish markets and is a leading Swedish specialist provider of high quality fresh proteins such as meat, fish and seafood to restaurants, hotels and cafés.

Vinge’s team consisted of Jonas Johansson, Carl Sander, Desirée Hagenfeldt and Robin Sultani (M&A) and Karl-Gustaw Tobola (Bank & Financing) as well as Julia Hagelberg, Emy Rydén and Anna Ekdahl Roos (project assistants).

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026